Related coverage linked through entity extraction aliases.
Jun 09, 2026
The Australian government announced an additional $387.4 million for CSIRO over four years and $12.7 million for eight quantum technology projects under the Critical Technologies Challenge Program, part of its broader National Quantum Strategy commitment.
Jun 07, 2026
The FDA announced new enforcement priorities on February 6, 2026, to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs being mass-marketed. The action follows an August 2025 citizens' petition arguing that large-scale compounded semaglutide production poses public health risks including lack of immunogenicity assessments and misleading marketing practices.
Jun 03, 2026
A large international study published in eClinicalMedicine found that COVID-19 booster vaccination was tied to a 33% lower risk of preeclampsia in pregnant women across 18 countries. Getting COVID during pregnancy increased preeclampsia risk by 78% in unvaccinated women, but vaccination with a booster reduced those odds significantly.
May 31, 2026
MannKind Corporation announced FDA approval of Afrezza inhaled mealtime insulin for pediatric patients with diabetes ages 6 and older. The approval makes Afrezza the first needle-free mealtime insulin alternative for children in over 100 years. Eligible patients can access Afrezza for $35 or less per month.
May 30, 2026
UCLA-led research finds telemedicine has not significantly increased healthcare visits or costs across all payer types from 2019-2023, published in JAMA Network Open. A separate study of Medicare patients reveals nearly half of telehealth visits are for non-mental health conditions, particularly chronic diseases like diabetes and high blood pressure. Both findings address questions about telehealth's role and impact since the COVID-19 pandemic.
May 20, 2026
The CONDOR randomized clinical trial found brolucizumab better preserved visual acuity than panretinal photocoagulation in proliferative diabetic retinopathy at week 54. Brolucizumab also reduced vision-threatening complications and center-involved diabetic macular edema events, while showing more intraocular inflammation.
May 14, 2026
U.S. insulin glargine and biosimilar developments in 2026 included CivicaScript's low-cost launch and California's CalRx rollout. The global insulin biosimilars market reached US$2.5 billion in 2025 and is projected to reach US$6.0 billion by 2033.
May 12, 2026
A study of 100 adults with diabetes found broad comfort with AI-based diabetic retinopathy screening, but most participants wanted physician oversight. The findings come as AI tools move further into community diabetes care.
May 12, 2026
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
May 05, 2026
Two studies of older adults with type 2 diabetes linked diabetic retinal disease with higher dementia risk. DME and more severe diabetic retinopathy were associated with higher all-cause and vascular dementia risk, but not consistently with Alzheimer’s disease.
May 04, 2026
The FDA said one pivotal trial plus confirmatory evidence will become the default standard for approval of most new drugs. The shift could extend beyond rare diseases to common conditions affecting millions.
May 02, 2026
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Apr 27, 2026
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
Apr 25, 2026
A study in Ophthalmology found tirzepatide use was associated with lower 12-month risk of new or progressive diabetic retinopathy versus lifestyle intervention alone. The analysis included about 174,000 matched patients.
Apr 25, 2026
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
Apr 24, 2026
Research and survey data point to lifelong learning, midlife stimulating activities and treatment of health risks as factors linked to better brain health and lower dementia risk.
Apr 24, 2026
The US pharmaceutical drug delivery market is projected to rise from USD 0.94 billion in 2026 to USD 1.24 billion by 2031 at a 5.8% CAGR. Injectables, oncology applications, and home care settings are expected to post the fastest growth.
Apr 24, 2026
A meta-analysis in BMC Ophthalmology found distinct gut microbiome compositional and functional alterations in diabetic retinopathy. The review identified depleted SCFA-producing bacteria, enriched pro-inflammatory bacteria, and dysregulated metabolic pathways.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Apr 22, 2026
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
